KateMurray

About Kate Murray

This author has not yet filled in any details.
So far Kate Murray has created 68 blog entries.

Remembering Charlie: The Leitis family shares their story

Dani and Charlie pose for a selfieBefore they knew what mitochondrial disease was, Dani and Ivars Leitis had what they considered to be the perfect family. Their daughter, Riley, was thrilled to have become a big sister at the age of seven, and baby Charlie (born June 4, 2021) was reaching all his milestones. “Everything in our lives was going well,” says Ivars. “We didn’t have everything, but we had it all.”

“We had no clue that Charlie was silently fighting a battle that would lead to a devastating loss,” says Dani. Charlie smiles to the camera as Ivars holds him

Charlie was big on snuggles and loved being held. “His favourite place was intently watching the world over Ivars’ left shoulder,” says Dani. “He had the greatest smile and laugh and big beautiful eyes. He was always watching what was going on around him.”

Charlie loved to make music, hum along to songs, play with his toys and the family’s dog Dusty, and scoot down the hall to his big sister’s room to see her. “The way Charlie’s face lit up for Riley was filled with pure love,” says Dani. Riley loved to give him piggyback rides, which were guaranteed to make him smile or laugh.

While Charlie was a happy, playful toddler, he faced challenges from the start. “He was very demanding in his first year as he was extremely fussy,” says Dani. “He struggled with breastfeeding. He seemed to get tired, as though it was a lot of work, and we ended up having to supplement with formula. We noticed he sometimes made a gurgling noise when he was breathing, but we were told that he just had underdeveloped vocal cords because he was premature. He had a ‘slight nystagmus’ we were told, which is involuntary eye movement. He also had what we thought were breath-holding spells. He’d cry so hard he’d stop breathing.

As it continued to progress, he’d go completely stiff – arching his back, his hands and toes would curl up and he looked like all the muscles in his body were seizing.” A visit to the family doctor sent Charlie into one of these spells. Witnessing it in person, the doctor became concerned that Charlie may be having seizures and referred him to a pediatrician. This would be the first time a pediatrician would dismiss concerns without any testing.

“Charlie started to seem a lot better after his first birthday,” says Dani. “The gurgle was gone and the breath-holding spells had nearly stopped. He continued meeting his milestones. But somewhere after the 16-month mark, we started noticing that Charlie was losing weight. He had been walking with support since 10 months but wouldn’t progress.  He also wasn’t using his words anymore. It happened so quickly.” The family doctor once again put in referrals for pediatricians, but it wouldn’t be until 19 months – January 2023, with desperate pleas from the family doctor – that two more pediatricians would finally accept Charlie as a patient. Charlie smiles for the camera

The family’s concerns were mostly dismissed by the first pediatrician they saw and they were told to check back in four months. Unfortunately, Charlie didn’t have four months.

Unsatisfied, the family moved on to a third pediatrician. She ordered blood work, tests, and referrals, including a dietitian and an occupational therapist (OT) who would support the family at home. The OT noticed that Charlie slouched a lot in his highchair, causing fatigue, and that his oral muscles were taking a long time to fire at the beginning of a meal. They switched from a highchair to a booster chair, added dietitian-provided supplements, and incorporated special foods to wake up his muscles, along with unlimited amounts of his favourite foods – chicken nuggets, chocolate chip panettone, and chocolate milk – to increase calories. Charlie started gaining weight quickly. “He was even napping less,” says Dani. “We started noticing him figuring out new ways to move and engage with things and people.”

The Leitis’ optimism was high until March of 2023, when Charlie came down with COVID. Although he appeared to have recovered from the virus, he had a lingering cough and the gurgling was back. After a particularly difficult morning with his cough, the Leitis family took Charlie to McMaster Children’s Hospital for the first time. Charlie was prescribed a steroid inhaler in addition to a rescue inhaler he was already on, and they were sent on their way. Charlie smiles for the camera

Charlie appeared to start recovering and relief was setting in until late one evening he started choking more on his fluids at dinner. That night, Dani and Ivars were woken multiple times to Charlie screaming in his sleep, much like he was having a night terror – something his sister had experienced as a toddler.

The next morning, Charlie was not himself. “He had no interest in food,” Dani recalls. “He wouldn’t settle to nap and his breathing seemed weird. His eyelids were heavy and he was staring blankly at me.”

Dani took Charlie to the hospital, and Ivars met her there. Charlie was admitted right away. His oxygen was just 39%. Doctors were perplexed as he was not presenting like anyone with such low oxygen. Charlie would eventually be intubated. During this process, concerns arose that he may have suffered a seizure, but it was never confirmed.

Charlie spent two weeks in the hospital while doctors and specialists tried to determine the cause of his distress. His lungs were full of fluid, causing his left lung to collapse and bringing focus there, until an MRI test showed that his brain stem (which controls the lungs, speech, swallowing, eye movement, and more) was covered in lesions. With the damage to the brain stem, they couldn’t save his lung.

Charlie never came home. He earned his angel wings on April 10, 2023. The beloved little boy passed away in the arms of his mom, dad, and sister, two months short of turning two. Charlie and Riley smile for a photograph

Months later, his family received Charlie’s official diagnosis of Leigh syndrome, a rare and fatal genetic mitochondrial disease with no cure. Charlie’s Leigh syndrome was due to a gene deletion, making it an exceptionally rare case.

When asked if there’s anything they know now that they wish they’d known before, the Leitis family found it a difficult question. Charlie lived a normal life for a toddler.

Charlie holds on to Ivars during a Blue Jays GameThe family went to Sauble Beach, Santa’s Village, Canada’s Wonderland, Niagara Falls, and a Blue Jays game. Charlie took a music class, spent life at a dance studio, and saw Riley dance in two recitals. “These are all things that we wouldn’t have felt safe doing had we known he was immunocompromised,” says Dani.

“We often wonder whether we could have better protected him had we known sooner, but in us not knowing, Charlie was able to enjoy a better quality of life. We want to continue Charlie’s life by sharing his story,” says Ivars, “and we hope that sharing his story makes a difference in the life of another child. Our hope is that through his story and better awareness, health care specialists will see the signs and symptoms sooner.”

© MitoCanada 2024. Shared with permission. Not for reuse or adaptation without consent.

MitoCanada’s 2026 Community Insights Survey

MitoCanada’s NEW Community Insights Survey

At MitoCanada, the voices of patients, families, caregivers, and researchers guide everything we do. To continue building programs, resources, and advocacy efforts that truly reflect the needs of our community, we launched our Canadian Community Insights Survey in 2025.

The results from this survey will directly shape our 2026 Canadian Community Insights Report, a key tool for understanding the realities of mitochondrial disease in Canada and driving change where it’s most needed.

Why Your Voice Matters

This survey was carefully designed in collaboration with individuals living with mito, parents and caregivers, and researchers. Each group provided input and guidance to make sure the questions capture what matters most.

By taking part, you will help us better understand:

  • Demographics of Canada’s mitochondrial community

  • The diagnostic journey and its challenges

  • The current mitochondrial disorder landscape

  • Experiences with the therapeutic landscape

  • Interest in clinical trial and research engagement

  • The quality of life impacts of living with mito

Your responses will fuel our efforts to advocate for better care, advance research, and support families across Canada.

How to Participate – Take the Survey

Click the link below to take the survey. On average, it takes about 12 minutes to complete, and your insights will have a lasting impact on the future of mitochondrial disease support and advocacy in Canada.

To recognize and honour the journeys of those we’ve lost, we’ve created a dedicated survey for families who have experienced loss. By sharing your experiences, you’ll help strengthen support for families and caregivers, and shape the future of research, advocacy, and care

Together, We Can Make a Difference

Every voice in our community matters. By sharing your experiences, challenges, and hopes, you’re helping us create a world where all lives are powered by healthy mitochondria.

Thank you for being part of this important work.

If you would like to learn more about our Community Insights Reports, we invite you to read our 2022 Community Insights Report

MitoCanada’s First Community Insights Report

MitoCanada’s First Community Insights Report

MitoCanada’s 2022 Community Insights Report brings together findings from a national consultation designed to better understand the needs of the Canadian mitochondrial disease community. Through interviews and survey data, the report highlights the complexity of the diagnostic journey, variations in treatment approaches, and the significant physical, emotional, and financial impacts of mitochondrial disease.

Key insights reveal long and often delayed diagnoses, particularly among adults, high reliance on individualized treatment strategies such as the mito cocktail, and widespread impacts on quality of life, including fatigue, muscle weakness, isolation, and loss of independence.

The report also identifies strong community demand for improved education, support, and advocacy.

This report is grounded in the voices of the Canadian mito community. Through a combination of one-on-one interviews and a national survey, MitoCanada engaged individuals living with mitochondrial disease, as well as parents and caregivers, to better understand their lived experiences.

The consultation was developed collaboratively with patient-partners, caregivers, and researchers to ensure that the questions reflected real community priorities. Participants from across Canada contributed, helping to build a national picture of the challenges and opportunities facing those affected by mitochondrial disease.

Read the full report to learn more about how the consultation was conducted

The consultation provides valuable insight into the composition of the Canadian mito community. Most participants were either adults living with mitochondrial disease or parents reporting on behalf of their children. The community is largely concentrated in urban centres, though access to care in rural and smaller regions remains an important consideration.

Age distribution shows two key groups: children aged 6–12 and adults aged 45–54. Over half of participants reported no known family history of mitochondrial disease, highlighting the complexity and variability of these conditions.

Read the full report to explore detailed demographic insights

The path to diagnosis varies widely, and is often prolonged. While some children are diagnosed within one to three years, many adults experience diagnostic journeys exceeding seven years.

Participants reported a range of diagnostic methods, including genetic testing, muscle biopsy, and biochemical testing. Even among those without a confirmed diagnosis, many continue to pursue testing or are treated based on symptoms. These findings highlight the need for improved awareness, earlier recognition, and more streamlined diagnostic pathways.

Read the full report to better understand diagnostic challenges and timelines

Treatment approaches for mitochondrial disease are highly individualized. The majority of participants reported being prescribed the mito cocktail, though perceptions of its effectiveness varied.

In addition to supplements, many individuals rely on therapies such as physiotherapy, occupational therapy, and exercise to manage symptoms. Exercise, in particular, was identified as one of the most helpful strategies, though it must be carefully balanced with rest due to fluctuating energy levels.

Financial burden is also a key issue, with many individuals paying out-of-pocket for treatments due to inconsistent provincial coverage.

Read the full report to explore the treatment landscape and access challenges

Mitochondrial disease has a profound impact on quality of life, both physically and emotionally. Muscle weakness and fatigue were identified as the most significant physical symptoms, while isolation, loss of independence, and helplessness were among the most commonly reported invisible impacts.

Families often face difficult trade-offs, including financial strain from medical costs and lifestyle adjustments to support care needs. These findings reinforce the importance of holistic support systems that address both medical and psychosocial challenges.

Read the full report to understand the full impact on daily life

Community members rely on a variety of sources for information, with MitoCanada identified as a primary and trusted resource. Interestingly, fewer participants reported relying on specialists for condition-specific education.

When asked about future needs, three clear priorities emerged:

  • Community support
  • Advocacy, and
  • Education

These areas reflect a strong desire for connection, improved awareness, and access to reliable, practical information.

Read the full report to explore community priorities in detail

Based on the insights gathered, MitoCanada identified several key areas for action, including:

  • Increasing public awareness of mitochondrial disease
  • Improving physician education to support earlier diagnosis
  • Developing practical disease management tools
  • Strengthening community connections
  • Advancing patient-centred research
  • Addressing inequities in access to care and coverage

These recommendations provide a roadmap for improving outcomes and ensuring that future efforts are aligned with community needs.

Read the full report to review all recommendations and next steps

This report reinforces a powerful truth: individuals and families living with mitochondrial disease are the true experts in their experience. Their voices highlight both the challenges they face and the opportunities to improve care, support, and research.

MitoCanada remains committed to listening, learning, and acting on these insights to help improve the journey for the mito community across Canada.

Read the full report to explore the complete findings

Go to Top